Southern Health NHS Foundation Trust

SH CP 249

Physical Health Monitoring for Psychotropic Medication

Version: 2

Summary	Guidelines for the physical health monitoring of adult patients on antipsychotics medicines	
Keywords	Antipsychotics, psychotropic, physical health, valproate, lithium, adult, olanzapine, venlafaxine, lamotrigine	
Target audience	All clinical staff	
Date issued	December 2021	
Approved & Ratified by	Medicines Management Committee Area Prescribing Committee District Prescribing Committee	**Date of meeting:** 10 November 2021
Next review date	December 2022	
Author	Juliet Wells, Principal Pharmacist	
Executive Director	Dr Steve Tomkins, Chief Medical Officer	

Version Control

Change Record

Date	Author	Version	Page	Reason for Change
Sep 2019	J Wells	New Policy	Throughout	Updated around latest Valproate PPP risks. Removed SSRI & TCAs. Updated agreed guidance, to include proforma. Clarified that does not include Clozapine & HDAT.
Nov 2019	J Wells		4	Amendments to clarify Olanzapine
Dec 2019	J Wells		4	Clarify for APC that pharmacists should check Lithium levels as part of the supply process. Re-arranged order of columns
June 2020		1		Previously published on CCG websites, updated and transferred onto trust template
24/9/20		1	5	Corrected a typo in bullet 6
17/5/21	P. Abeywardana	2	4 5	Added Duloxetine and Pulse to table. Added A to valproate and annually to the definition of A Added pregnancy to bullet 9
June 2021	S. Masterson	2	4	Added reminder to record in results in the Lithium booklet, under the Li subheading in the table
Aug/ Nov 2021	J. Wells M. Webb	2 2	4 4, 5	Lithium blue box – Na added to 4th bullet. C, added frequency. Valproate purple box – hot link for PPP added. New reference included, SPS monitoring. Initial (blue) line reviewed to include specifics around individuals and CLDT patients. Bullet 14 added to repeat this.

Reviewers/contributors

Name	Position	Version Reviewed & Date
Medicines Management Committee		V1
Medicines Management Department		V1
Dr Karl Marlowe	Chief Medical Officer SHFT	V1 Sept 2019
Dr Jeremy Rowland	Medical Director SHFT	V1 Sept 2019
Raj Shergill	Chief Pharmacist SHFT	V1 Sept 2019
Juliet Wells	Principal Pharmacist Mid & N SHFT	V1 Sept 2019
Dr Hanna Burgess	GP, Shirley Health Partnership, Southampton	V1 Sept 2019
Dr Emma Nash	GP, West Hampshire CCG	V1 Sept 2019
Graham Webb	Transformation Manager SHFT	V1 Sept 2019
Tracy Holbrook	Medicines Management Technician	V1 Sept 2019
Dr Katrina Webster	GP, West CCG Commissioner for Mental Health	V1 Sept 2019
Shane Masterson	Principal Pharmacist, Specialist Services Division, SHFT	V2 June 2021
Peter Abeywardana	Clinical Pharmacist, Melbury Lodge, SHFT	V2 May 2021
Mel Webb	Consultant Nurse, Learning Disabilities	V2 Nov 2021
Dr Saif Sharif	Consultant Psychiatrist, Learning Disabilities	V2 Nov 2021

Contents

Key

Abbreviation	Meaning
CMHT	Community Mental Health Team
CLDT	Community Learning Disability Team
HDAT	High Dose Antipsychotic Therapy
Ca	Calcium
OPD	Outpatient Department

PhysicalHealth Monitoring for Psychotropic Medication

Not for High Dose Antipsychotic Therapy (HDAT) or Clozapine

The Annual Health Check is recommended. Responsibility for medication monitoring and physical health checks lies with secondary care (CMHTs), where a patient has been under their care for 1 year or less, or their condition has not yet been stabilised, except where the patient is open to a CLDT or on a patient case by case need. For Clozapine and High Dose Antipsychotic Therapy (HDAT), the majority of monitoring remains in secondary care (see separate guidelines).

Medication	Frequency	BMI / weight	TFTs	U&Es/ eGFR	Ca	ECG	Lithium levels	FBC	HbA_{1c} Glucose	LFTs	Prolactin	BP Pulse	Lipids
	Secondary care												
Lithium* (record all levels and results in the patient's Lithium booklet)	Baseline	✓	✓	✓	✓	✓							
	Dose Change						weekly until stable						
	3 monthly						for 1st year or in Risk Groups*						
	6 monthly	✓	✓	✓	✓	B	✓ after 1st year						
	Annually	✓	✓	✓	✓	B	✓						
Valproate**	Baseline; PPP and Annual Risk Form	A						C		A			
Lamotrigine	Baseline; skin reaction advice							C					
Venlafaxine/ Duloxetine	Baseline	✓										✓	
	Post dose increase											✓	
	6 monthly After 1 year											✓	
Antipsychotics (for the most recent info check SPC for the specific drug)	Baseline & CV risk	✓		✓		✓		✓	✓	✓	✓	✓	✓
	During titration											✓	
	After 1 month	✓							olanzapine				
	3 months	✓							▲ olanzapine				✓
	6 months	olanzapine							✓		✓		olanzapine
	9 months	olanzapine											olanzapine
	Annually & CV risk	✓		✓		B		✓	✓	✓	✓	✓	✓

A = before therapy and during first six months thereafter annually, include prothrombin. Check prior to surgery.

B = only if CVD suspected, risk factors or existing cardiac problem, or haloperidol.

C = before therapy & during first six months, thereafter annually. Recognise signs of blood disorders: anaemia/bruising – provide info for patients. Check prior to surgery.

PPP = Pregnancy Prevention Plan.

CV risk = Cardiovascular risk assessment required e.g. current Q-risk tool.

SPC = summary of product characteristics.

▲ **Olanzapine requires monitoring every 4 – 6 months thereafter.**

* Risk Groups with Lithium Therapy

Require increased monitoring: -

- Older people
- Concurrent interacting drugs (NSAIDs, ACEIs, diuretics)
- At risk of renal or thyroid dysfunction, increasing Ca etc.
- Significant disease or change in fluid/food/Na intake
- Poor adherence or symptom control
- Last level greater than 0.8mmol/L

** Valproate Risks in Pregnancy

For all women/girls of child bearing potential: –

- An annual risk acknowledgement form by a specialist must be in place, with patient consent
- A Pregnancy Protection Plan (PPP) with effective contraception throughout treatment must be in place
- Patient to be informed, given a card and booklet, and agree to plan any pregnancy
- Patient reviewed annually by secondary care & a new form completed

SH CP 249 Physical Health Monitoring for Psychotropic Medication.
Created by SHFT NHS Agreed by all clinical commissioning groups across Hampshire, Southampton & IOW.
Version: 2
December 2021

Physical Health Monitoring for Psychotropic Medication (not HDAT/ Clozapine)

General Principles

This guidance has been developed using the current BNF no. 82, Summary of Product Characteristics 2021 and SPS Drug Monitoring guidance. The guidance is a minimum recommendation only and clinical need should override decisions on monitoring. In the interests of patient care, where systems are currently in place (and working to meet the minimum monitoring requirements), these should not be changed.

1. Clinicians should use medications that are both clinically and cost effective.
2. Monitoring involves advising patients where to get their bloods done, depending on local phlebotomy arrangements, arranging ECGs and acting on the results. Inform the patient and their GP as appropriate.
3. If a medication is recommended by a clinician in an outpatient clinic, a FP10 prescription will be for a minimum of 2 weeks' supply unless clinical risk dictates otherwise. The GP should be informed promptly of this (OPD letters to be transmitted within 7 days to ensure compliance with the NHS standard contract) and the patient given a proforma to deliver to the GP surgery. Even then patients may wait a week to get new supplies.
4. Secondary care will continue the monitoring until the patient is stable.
5. Ongoing prescriptions may be issued by primary care when the patient is appropriately stabilised on a dosage and the GP has been informed and has agreed to take over prescribing.
6. After discharge from secondary care, patients should receive advice on: required ongoing monitoring; dosage alterations where appropriate; how to access secondary care services again.
7. Re-refer to the appropriate secondary care service if required.
8. ECGs are only required when clinically indicated (see guide) and are the responsibility of the prescriber.
9. Where there are comorbid physical health issues or pregnancy (or planning for pregnancy), key specialists should be involved in the monitoring and the information shared, as appropriate.
10. The frequency of physical monitoring may need to be increased if you have clinical concerns.
11. Clozapine is a secondary care medication (red drug). Primary care needs to be aware that their patients are on it and of potential adverse effects and interactions. Clozapine should be added to the primary care record and SCR, where prescribed. See separate guidance.
12. Current shared care arrangements for Lithium will continue.
13. Care of a patient prescribed HDAT (>100% of BNF recommended doses of one or a combination of antipsychotics) is to remain under secondary care unless specifically agreed and this should be appropriately highlighted on the patient's GP record.
14. Specific arrangements may be needed for individual patients on a case by case basis, such as patients who are open to CLDTs.

3. Document review

The document will be reviewed annually, or sooner if changes in legislation occur or new best practice evidence becomes available.

4. Associated Trust documents

- SH CP 91 - Anxiety Treatment Guidelines: for people over the age of 18
- SH CP 92 - Bipolar Guidelines for adults aged 18 years or older
- SH CP 110 - Depression Management Guidelines
- SH CP 111- Antipsychotics Guidelines
- SH CP 113 - Shared Care Guidelines for Prescribing Lithium
- SH CP 136 - Guidelines for the Treatment of Primary Insomnia
- SH CP 189 - Antisocial and Borderline Personality Disorder Guidelines the Pharmacological Treatment

5. Supporting references (always check latest versions)

- Current BNF https://bnf.nice.org.uk/
- Current SPC https://www.medicines.org.uk/
- www.sps.nhs.uk/home/guidance/drug-monitoring/